Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et fase 1b/2-studie af BGB-11417 i monoterapi og i forskellige kombinationer med dexamethason og carfilzomib ved myelomatose

23. oktober 2026 opdateret af: BeOne Medicines

Et fase 1b/2-dosis-eskalerings- og kohorteudvidelsesstudie for at bestemme sikkerheden og effektiviteten af ​​BGB-11417 som monoterapi, i kombination med dexamethason og carfilzomib/dexamethason hos patienter med recidiverende/refraktært myelomatose og t)(11;

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).

The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.

Studieoversigt

Detaljeret beskrivelse

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

246

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australien, ACT 2605
        • Rekruttering
        • Canberra Hospital
    • New South Wales
      • Kingswood, New South Wales, Australien, NSW 2747
        • Rekruttering
        • Nepean Hospital
    • Victoria
      • Clayton, Victoria, Australien, VIC 3168
        • Rekruttering
        • Monash Health
      • Fitzroy, Victoria, Australien, VIC 3065
        • Rekruttering
        • St Vincents Hospital Melbourne
      • Melbourne, Victoria, Australien, VIC 3004
        • Rekruttering
        • The Alfred Hospital
    • Western Australia
      • Perth, Western Australia, Australien, WA 6000
        • Rekruttering
        • Royal Perth Hospital
      • Brasília, Brasilien, 70200-730
        • Rekruttering
        • Hospital Sirio Libanes Brasilia
      • Brasília, Brasilien, 70390140
        • Rekruttering
        • Instituto Dor de Pesquisa E Ensino Distrito Federal
      • Porto Alegre, Brasilien, 90110-270
        • Rekruttering
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Salvador, Brasilien, 41253-190
        • Rekruttering
        • Hospital Sao Rafael (Rede Dor)
      • São Paulo, Brasilien, 05652-900
        • Rekruttering
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasilien, 01401-004
        • Rekruttering
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
      • São Paulo, Brasilien, 01308-050
        • Rekruttering
        • Hospital Sirio Libanes
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Rekruttering
        • Cross Cancer Institute
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Rekruttering
        • British Columbia Cancer Agency the Vancouver Centre
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • Princess Margaret Cancer Centre
      • Headington, Det Forenede Kongerige, OX3 7LE
        • Rekruttering
        • Oxford University Hospitals Nhs Trust Churchill Hospital
      • London, Det Forenede Kongerige, NW1 2PG
        • Rekruttering
        • University College Hospital
      • Sutton, Det Forenede Kongerige, SM2 5PT
        • Rekruttering
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294-0004
        • Rekruttering
        • University of Alabama At Birmingham Hospital
    • California
      • Duarte, California, Forenede Stater, 91010-3012
        • Rekruttering
        • City of Hope National Medical Center
      • Irvine, California, Forenede Stater, 92618-2377
        • Rekruttering
        • City of Hope Irvine Lennar
    • Florida
      • Miami, Florida, Forenede Stater, 33136-2107
        • Rekruttering
        • University of Miami
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322-1013
        • Rekruttering
        • Emory University Winship Cancer Center
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637-1443
        • Rekruttering
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Afsluttet
        • Massachusetts General Hospital
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110-1010
        • Rekruttering
        • Washington University School of Medicine
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601-1915
        • Rekruttering
        • Hackensack University Medical Center
    • New York
      • New York, New York, Forenede Stater, 10065-6800
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center Mskcc
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210-1240
        • Rekruttering
        • The James Cancer Hospital and Solove Research Institute At Ohio State University
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112-5550
        • Rekruttering
        • Huntsman Cancer Institute
    • Washington
      • Seattle, Washington, Forenede Stater, 98195
        • Rekruttering
        • University of Washington
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792-0001
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center
      • Milwaukee, Wisconsin, Forenede Stater, 53226-3522
        • Rekruttering
        • Medical College of Wisconsin
      • Poitiers, Frankrig, 86000
        • Afsluttet
        • Chu de Poitiers Site de La Mileterie
      • Alexandroupoli, Grækenland, 68100
        • Rekruttering
        • University Hospital of Alexandroupolis
      • Athens, Grækenland, 115 28
        • Rekruttering
        • General Hospital of Athens Alexandra
      • Ancona, Italien, 60020
        • Rekruttering
        • Azienda Ospedaliera Universitaria Delle Marche
      • Bari, Italien, 70124
        • Rekruttering
        • Azienda Ospedaliera Policlinico Di Bari
      • Bologna, Italien, 40138
        • Rekruttering
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Meldola, Italien, 47014
        • Rekruttering
        • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
      • Milan, Italien, 20141
        • Rekruttering
        • Istituto Europeo Di Oncologia
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100044
        • Rekruttering
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, Kina, 100000
        • Rekruttering
        • Peking University Third Hospital
      • Beijing, Beijing Municipality, Kina, 100020
        • Rekruttering
        • Beijing Chao Yang Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina, 400030
        • Rekruttering
        • Chongqing Cancer Hospital
    • Fujian
      • Fuzhou, Fujian, Kina, 350001
        • Afsluttet
        • Fujian Medical University Union Hospital
      • Xiamen, Fujian, Kina, 361003
        • Afsluttet
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510060
        • Rekruttering
        • Sun Yat Sen University Cancer Center
    • Hebei
      • Shijiazhuang, Hebei, Kina, 050000
        • Afsluttet
        • The Second Hospital of Hebei Medical University
    • Henan
      • Zhengzhou, Henan, Kina, 450000
        • Rekruttering
        • Henan Cancer Hospital
      • Zhengzhou, Henan, Kina, 450052
        • Aktiv, ikke rekrutterende
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, Kina, 430022
        • Rekruttering
        • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, Kina, 410013
        • Afsluttet
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Rekruttering
        • Jiangsu Province Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 332000
        • Rekruttering
        • The First Affiliated Hospital of Nanchang University Branch Xianghu
    • Liaoning
      • Shenyang, Liaoning, Kina, 110001
        • Rekruttering
        • The First Hospital of China Medical University
    • Shandong
      • Qingdao, Shandong, Kina, 266000
        • Rekruttering
        • Qingdao Municipal Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekruttering
        • Affiliated Zhongshan Hospital of Fudan University
      • Shanghai, Shanghai Municipality, Kina, 200434
        • Afsluttet
        • Shanghai Fourth Peoples Hospital Affiliated to Tongji University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 301617
        • Rekruttering
        • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
      • Tianjin, Tianjin Municipality, Kina, 300052
        • Afsluttet
        • Tianjin Medical University General Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310003
        • Rekruttering
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Singapore, Singapore, 119074
        • Rekruttering
        • National University Hospital Singapore
      • Barcelona, Spanien, 08036
        • Aktiv, ikke rekrutterende
        • Hospital Clinic de Barcelona
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, Sydkorea, 06351
        • Rekruttering
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, Sydkorea, 06591
        • Rekruttering
        • The Catholic University of Korea, Seoul St Marys Hospital
      • SeodaemunGu, Seoul Teugbyeolsi, Sydkorea, 03722
        • Rekruttering
        • Severance Hospital Yonsei University Health System
      • Seoul, Seoul Teugbyeolsi, Sydkorea, 03080
        • Rekruttering
        • Seoul National University Hospital
      • SongpaGu, Seoul Teugbyeolsi, Sydkorea, 05505
        • Rekruttering
        • Asan Medical Center
      • Aachen, Tyskland, 52074
        • Rekruttering
        • Universitaetsklinikum Aachen
      • Dresden, Tyskland, 01307
        • Rekruttering
        • Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
      • Hamburg, Tyskland, 20251
        • Rekruttering
        • Universitatsklinikum Hamburg Eppendorf
      • Würzburg, Tyskland, 97080
        • Rekruttering
        • Universitatsklinikum Wurzburg

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

  2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)

  3. Measurable disease defined as:

    i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio

  4. Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.

    i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.

    ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.

    1. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
    2. Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
    3. Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
  5. Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory

    a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.

  6. Adequate organ function defined as:

    1. Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
    2. Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
    3. Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)

Exclusion Criteria:

  1. Participant has any of the following conditions:

    1. Non secretory MM (Serum free light chains < 10 mg/dL)
    2. Solitary plasmacytoma
    3. Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
    4. Waldenström macroglobulinemia (WM)
    5. Amyloidosis.
    6. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
    7. Chronic respiratory disease that requires continuous oxygen
  2. Significant cardiovascular disease, including but not limited to:

    1. Myocardial infarction ≤ 6 months before screening
    2. Ejection fraction ≤ 50%
    3. Unstable angina≤ 3 months before screening
    4. New York Heart Association Class III or IV congestive heart failure
    5. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    6. Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
    7. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
    8. Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
  3. Known infection with human immunodeficiency virus (HIV)

  4. Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:

    1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
    2. Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

Administered orally daily

Andre navne:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

Administered subcutaneously weekly

Administered orally daily

Eksperimentel: Part 2 Cohort Expansion

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

Administered orally daily

Andre navne:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Del 1 og 2: Antal deltagere, der rapporterer om en eller flere behandlingsmæssige bivirkninger (TEAE'er), alvorlige bivirkninger (SAE'er), bivirkninger, der fører til seponering og bivirkninger af særlig interesse (enese).
Tidsramme: Op til 30 dage efter sidste dosis af studiemedicin
Op til 30 dage efter sidste dosis af studiemedicin
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Tidsramme: Up to 28 days

DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol.

Up to 28 days
Part 2: Overall response rate (ORR) as Assessed by Investigator
Tidsramme: Approximately 4 years

Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria

Approximately 4 years
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Tidsramme: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]

Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR)

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Tidsramme: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

defined as the percentage of participants with a documented CR or sCR

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Del 1: Område under plasmakoncentrationstidskurve-tid 0 til den sidste målbare koncentration (AUCLAST) efter en enkelt dosis Sonrotoclax
Tidsramme: Cyklus 1 (hver cyklus er op til 28 dage)
Cyklus 1 (hver cyklus er op til 28 dage)
Del 1: Maksimal observeret plasmakoncentration (CMAX) efter en enkelt dosis Sonrotoclax
Tidsramme: Cyklus 1 (hver cyklus er op til 28 dage)
Cyklus 1 (hver cyklus er op til 28 dage)
Del 1: Tid til at nå Cmax (Tmax) efter en enkelt dosis Sonrotoclax
Tidsramme: Cyklus 1 (hver cyklus er op til 28 dage)
Cyklus 1 (hver cyklus er op til 28 dage)
Del 1: Ved stabil tilstand: AUC Last, SS
Tidsramme: Cyklus 2 (hver cyklus er op til 28 dage)
Cyklus 2 (hver cyklus er op til 28 dage)
Del 1: Ved stabil tilstand: Cmax, SS
Tidsramme: Cyklus 2 (hver cyklus er op til 28 dage)
Cyklus 2 (hver cyklus er op til 28 dage)
Del 1: Ved stabil tilstand: Trough Plasma Concentration (CTROUGH) SS
Tidsramme: Cyklus 2 (hver cyklus er op til 28 dage)
Cyklus 2 (hver cyklus er op til 28 dage)
Del 1: Ved stabil tilstand: Tid til at nå Cmax (Tmax, SS)
Tidsramme: Cyklus 2 (hver cyklus er op til 28 dage)
Cyklus 2 (hver cyklus er op til 28 dage)
Part 2: Time to response (TTR) as Assessed by Investigator
Tidsramme: Approximately 4 years

TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better

Approximately 4 years
Part 2: Duration of response (DOR) as Assessed by Investigator
Tidsramme: Approximately 4 years

DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method.

Approximately 4 years
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Tidsramme: Approximately 4 years

PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first

Approximately 4 years
Part 2: Overall survival (OS) as Assessed by Investigator
Tidsramme: Approximately 4 years

OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause

Approximately 4 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

16. september 2021

Primær færdiggørelse (Anslået)

1. november 2026

Studieafslutning (Anslået)

1. november 2026

Datoer for studieregistrering

Først indsendt

7. juli 2021

Først indsendt, der opfyldte QC-kriterier

20. juli 2021

Først opslået (Faktiske)

22. juli 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. oktober 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

IPD-delingstidsramme

See plan description

IPD-delingsadgangskriterier

See plan description

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner